Last reviewed · How we verify
Synergy for Neonatal Meningitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Tobi · Novartis
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Synergy for Neonatal Meningitis patent landscape — cliff calendar, originator estates, attackable patents
- Synergy for Neonatal Meningitis treatment landscape brief
- Synergy for Neonatal Meningitis treatment updates RSS
Frequently asked questions about Synergy for Neonatal Meningitis
What drugs treat Synergy for Neonatal Meningitis?
Tracked treatments include Ramycin, Garamycin, Tobi, Vantobra, Gentamicin, Nebcin.
What is the treatment for Synergy for Neonatal Meningitis?
Standard treatment for Synergy for Neonatal Meningitis includes Ramycin, Garamycin, Tobi, Vantobra, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Synergy for Neonatal Meningitis patent cliff · Synergy for Neonatal Meningitis CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing